113299-40-4

Basic information

• Product Name: (R)-Bicalutamide
• Synonyms: (R)-(-)-BICALUTAMIDE;(R)-BICALUTAMIDE;N-[4-Cyano-3-(Trifluoromethyl)Phenyl]-3-[(4-Flurophenyl)Thio]-2-Hydroxy-2-Methyl-Propanamide;R-BICALUTIMIDE;(R)-Casodex;Propanamide, N-[4-cyano-3-(trifluoromethyl)phenyl]-3-[(4-fluorophenyl)sulfonyl]-2-hydroxy-2-methyl-, (2R)-;Propanamide, N-[4-cyano-3-(trifluoromethyl)phenyl]-3-[(4-fluorophenyl)sulfonyl]-2-hydroxy-2-methyl-, (R)-;(2R)-N-[4-Cyano-3-(trifluoromethyl)phenyl]-3-[(4-fluorophenyl)sulfonyl]-2-hydroxy-2-methylpropanamide
• CAS NO: 113299-40-4
• Molecular Formula: C₁₈H₁₄F₄N₂O₄S
• Molecular Weight: 430.37
• EINECS: 1806241-263-5
• Product Categories: Chiral Reagents;Intermediates & Fine Chemicals;Pharmaceuticals;Sulfur & Selenium Compounds
• Mol File: 113299-40-4.mol
• Article Data: 12

Chemical Properties

• Melting Point: 178-181°C
• Boiling Point: 650.3 °C at 760 mmHg
• Flash Point: 347.1 °C
• Appearance: Off-white crystalline solid
• Density: 1.52 g/cm³
• Vapor Pressure: 8.47E-18mmHg at 25°C
• Refractive Index: 1.577
• Storage Temp.: -20?C Freezer
• Solubility: Acetone (Slightly), Ethyl Acetate (Slightly), Methanol (Slightly)
• PKA: 11.49±0.29(Predicted)
• CAS DataBase Reference: (R)-Bicalutamide(CAS DataBase Reference)
• NIST Chemistry Reference: (R)-Bicalutamide(113299-40-4)
• EPA Substance Registry System: (R)-Bicalutamide(113299-40-4)

Safety Data

• Hazardous Substances Data: 113299-40-4(Hazardous Substances Data)

Usage

Description

(R)-Bicalutamide, an off-white crystalline solid, is a non-steroidal antiandrogen and antineoplastic agent. It is a chiral molecule with a specific R-configuration, which plays a crucial role in its biological activity and selectivity.

Uses

Used in Pharmaceutical Industry:
(R)-Bicalutamide is used as an antiandrogen for the treatment of prostate cancer. It competitively inhibits androgen receptors, thereby reducing the growth of prostate cancer cells and alleviating symptoms associated with the disease.
(R)-Bicalutamide is also used as an antineoplastic agent, specifically as a hormonal therapy, to control the progression of hormone-sensitive tumors. Its ability to block androgen receptors helps in managing the growth of cancer cells that rely on androgen stimulation for their proliferation.

InChI:InChI=1/C18H14F4N2O4S/c1-17(26,10-29(27,28)14-6-3-12(19)4-7-14)16(25)24-13-5-2-11(9-23)15(8-13)18(20,21)22/h2-8,26H,10H2,1H3,(H,24,25)/t17-/m0/s1

Upstream product

• 824-80-6 sodium 4-fluorobenzenesulfinate 
• 206193-17-1 (2R)-3-bromo-N-[4-cyano-3-(trifluoromethyl)phenyl]-2-hydroxy-2-methylpropanamide 
• 90357-06-5 Bicalutamide 
• 335595-52-3 (R)-3-(4-fluorophenylmercapto)-2-hydroxy-2-methylpropionic acid 
• 654-70-6 4-amino-2-trifluoromethylbenzonitrile 
• 371-42-6 4-Fluorothiophenol 
• 928312-15-6 C₁₀H₁₃FO₄S 
• 928312-14-5 C₁₇H₁₉FO₄S 
• 928312-13-4 C₁₇H₁₉FO₂S 
• 890658-79-4 C₁₀H₁₁FO₅S 

Downstream Products

• 1226897-60-4 phosphoric acid ester of (R)-bicalutamide 
• 1259485-93-2 O-dibenzyl phosphoric acid ester of (R)-bicalutamide 

Relevant articles and documents

Preparation method of (R)-bicalutamide intermediate

The invention relates to a method for preparing an (R)-bicalutamide intermediate. The method comprises the following steps: taking methacrylic acid as a raw material, and obtaining the (R)-bicalutamide intermediate through several steps of esterification, hydroxylation and sulfonation, namely, (R)-3-(4-fluorophenylsulfydryl)-2-hydroxy-2-methylpropionic acid. (R)-bicalutamide with enantioselectivity of more than 99% can be obtained by two simple follow-up reactions of the intermediate. The preparation method has the advantages of easily available starting materials, high reaction yield, easy operation in reaction, high enantioselectivity and wide industrial application prospects.

Preparation of a novel bridged bis(β-cyclodextrin) chiral stationary phase by thiol-ene click chemistry for enhanced enantioseparation in HPLC

A bridged bis(β-cyclodextrin) ligand was firstly synthesized via a thiol-ene click chemistry reaction between allyl-ureido-β-cyclodextrin and 4-4′-thiobisthiophenol, which was then bonded onto a 5 μm spherical silica gel to obtain a novel bridged bis(β-cyclodextrin) chiral stationary phase (HTCDP). The structures of HTCDP and the bridged bis(β-cyclodextrin) ligand were characterized by the 1H nuclear magnetic resonance (1H NMR), solid state 13C nuclear magnetic resonance (13C NMR) spectra spectrum, scanning electron microscope, elemental analysis, mass spectrometry, infrared spectrometry and thermogravimetric analysis. The performance of HTCDP in enantioseparation was systematically examined by separating 21 chiral compounds, including 8 flavanones, 8 triazole pesticides and 5 other common chiral drugs (benzoin, praziquantel, 1-1′-bi-2-naphthol, Tr?ger's base and bicalutamide) in the reversed-phase chromatographic mode. By optimizing the chromatographic conditions such as formic acid content, mobile phase composition, pH values and column temperature, 19 analytes were completely separated with high resolution (1.50-4.48), in which the enantiomeric resolution of silymarin, 4-hydroxyflavanone, 2-hydroxyflavanone and flavanone were up to 4.34, 4.48, 3.89 and 3.06 within 35 min, respectively. Compared to the native β-CD chiral stationary phase (CDCSP), HTCDP had superior enantiomer separation and chiral recognition abilities. For example, HTCDP completely separated 5 other common chiral drugs, 2 flavanones and 3 triazole pesticides that CDCSP failed to separate. Unlike CDCSP, which has a small cavity (0.65 nm), the two cavities in HTCDP joined by the aryl connector could synergistically accommodate relatively bulky chiral analytes. Thus, HTCDP may have a broader prospect in enantiomeric separation, analysis and detection. This journal is

Design and synthesis of novel bicalutamide and enzalutamide derivatives as antiproliferative agents for the treatment of prostate cancer

Prostate cancer (PC) is one of the major causes of male death worldwide and the development of new and more potent anti-PC compounds is a constant requirement. Among the current treatments, (R)-bicalutamide and enzalutamide are non-steroidal androgen receptor antagonist drugs approved also in the case of castration-resistant forms. Both these drugs present a moderate antiproliferative activity and their use is limited due to the development of resistant mutants of their biological target. Insertion of fluorinated and perfluorinated groups in biologically active compounds is a current trend in medicinal chemistry, applied to improve their efficacy and stability profiles. As a means to obtain such effects, different modifications with perfluoro groups were rationally designed on the bicalutamide and enzalutamide structures, leading to the synthesis of a series of new antiproliferative compounds. Several new analogues displayed improved in vitro activity towards four different prostate cancer cell lines, while maintaining full AR antagonism and therefore representing promising leads for further development. Furthermore, a series of molecular modelling studies were performed on the AR antagonist conformation, providing useful insights on potential protein-ligand interactions.